Vor Biopharma
Market cap $1.12B 61.4M shares (10-Q, Oct 26, 2026) × $18.18 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- telitacicept Ph3 topline1H 2027telitacicept Ph3 topline, 1H 2027, thesis-defining
- UPSTREAM MG Ph3 topline1H 2027UPSTREAM MG Ph3 topline, 1H 2027, major
- RemeGen warrants FDA approval~1Q 2027RemeGen warrants FDA approval, ~1Q 2027, material
- RC298 IND filing1H 2027RC298 IND filing, 1H 2027, notable
- UPSTREAM oMG pivotal start1H 2027UPSTREAM oMG pivotal start, 1H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
Discontinued (4)
- tremtelectogene empogeditemcel — Acute Myeloid Leukemia · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- tremtelectogene empogeditemcel — Myelodysplastic Syndrome · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- VCAR33 — Acute Myeloid Leukemia · winddown of prior clinical and manufacturing operations announced May 8, 2025; IP sold in August/September 2025
- VADC45 — undisclosed · winddown of prior clinical and manufacturing operations; IP sold in August/September 2025
Capital (as filed)
- Cash
- $79.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $403M Sep 30, 2026
- Operating cash flow
- −$32.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $482M cash, runway early 2029 per the update of Oct 30, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
- 2026-10-30 424B5 · At-the-market program up to $150M
- 2026-09-04 S-3ASR · Shelf registration
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-13 UPDATE: Vor Bio (VOR) - Buying the Sequel Before the Premiere 🔒 Paid
- 2026-10-30 UPDATE: Vor Bio (VOR) - The ATM Gets Reloaded 🔒 Paid
- 2026-10-23 UPDATE: Vor Bio (VOR) - The Kidney Clock Nearly Stops ★ Distilled Pro
- 2026-09-09 UPDATE: Vor Bio (VOR) - The Enrollment Clock Stops 🔒 Paid
- 2026-08-12 UPDATE: Vor Bio (VOR) - They Sold Into the Rip 🔒 Paid
- 2026-07-21 UPDATE: Vor Bio (VOR) - RA Answers the Watch Item 🔒 Paid
- 2026-07-07 UPDATE: Vor Bio (VOR) - The Anchor Leaves, the Closer Arrives 🔒 Paid
- 2026-06-08 UPDATE: Vor Bio (VOR) - The Free Look Pays Off Twice 🔒 Paid
- 2026-05-15 UPDATE: Vor Bio (VOR) - NEJM Stamps the Free Look 🔒 Paid
- 2026-04-27 UPDATE: Vor Bio (VOR) - The Anchor is Selling 🔒 Paid
- 2026-04-06 Vor Bio (VOR) - Scientific Deep Dive Fortelitacicept and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Vor Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-06 Watch Vor Bio (VOR) - Scientific Deep Dive Fortelitacicept and Pipeline Products Telitacicept's dual BAFF/APRIL biology is compelling but the 2028 composition-of-matter patent cliff, CMC tech transfer risk, and demographic translation uncertainty warrant waiting for enrollment and manufacturing clarity before committing capital.
- 2026-04-27 Watch UPDATE: Vor Bio (VOR) - The Anchor is Selling RA Capital's aggressive selling of directly-held common stock muddies the conviction signal without changing the underlying science or cash thesis, warranting continued caution on the sidelines.
- 2026-05-15 Speculative buy speculative UPDATE: Vor Bio (VOR) - NEJM Stamps the Free Look NEJM publication of TELIGAN Phase 3 IgAN data with 55% placebo-adjusted proteinuria reduction and eGFR preservation materially de-risks the dual BAFF/APRIL biology and upgrades the pipeline-in-a-product narrative from marketing to investable.
- 2026-06-08 Speculative buy speculative UPDATE: Vor Bio (VOR) - The Free Look Pays Off Twice Two simultaneous NMPA approvals (IgAN and SjD) give telitacicept five approved indications in China, with SjD being the first approved systemic therapy globally, further compounding biological and regulatory de-risking while the price has weakened.
- 2026-07-07 Speculative buy speculative UPDATE: Vor Bio (VOR) - The Anchor Leaves, the Closer Arrives Levin's board resignation removes the last governance signal of RA Capital's commitment, but Zaccardelli's appointment — a CEO with three strategic exits including a $10B Merck deal — sharpens the M&A exit optionality and adds manufacturing expertise to address the CMC silent-killer risk.
- 2026-07-21 Speculative buy speculative UPDATE: Vor Bio (VOR) - RA Answers the Watch Item RA Capital's cashless exercise of 2.1M pre-funded warrants into common stock is the opposite of walking off the field, shifting the RA read from bearish-at-governance-level to ambiguous and modestly constructive.
- 2026-08-12 Speculative buy speculative UPDATE: Vor Bio (VOR) - They Sold Into the Rip Management's $48.9M ATM raise at $19.11 confirms dilution appetite rather than a dilution gap, while enrollment remains on track for 1H27 and commercial build-out spending signals a credible launch-or-sell narrative ahead of the binary.
- 2026-09-09 Speculative buy speculative UPDATE: Vor Bio (VOR) - The Enrollment Clock Stops UPSTREAM MG is fully enrolled and the 1H27 topline is now arithmetic rather than guidance, retiring enrollment slippage risk while the demographic translation question — whether a -4.8 MG-ADL delta from Chinese patients replicates in Western populations — remains entirely unanswered.
- 2026-10-23 Speculative buy speculative UPDATE: Vor Bio (VOR) - The Kidney Clock Nearly Stops Two-year TELIGAN eGFR slope data (-0.6 vs -5.7 mL/min/1.73m²/year, p<0.001) converts the proteinuria surrogate win into hard organ-function proof, delivering the strongest biological validation yet while the stock has pulled back 24.5% from its September high.
- 2026-10-30 Speculative buy speculative UPDATE: Vor Bio (VOR) - The ATM Gets Reloaded A new $150M ATM facility confirms management's willingness to sell paper into strength ahead of the 1H27 binary, creating a supply overhang that could cap rallies, though the balance sheet doesn't need the cash and the clinical timeline remains locked.
- 2026-11-13 Speculative buy speculative UPDATE: Vor Bio (VOR) - Buying the Sequel Before the Premiere Vor's ~$56M acquisition of RC298, a preclinical long-acting TACI-Fc successor, is a credibly priced option on the 2028 patent cliff problem, but the asset is years from proof and every new program depends on telitacicept winning in UPSTREAM MG.
- Long call · opened May 15, 2026 at $14.63 · +24.3% vs XBI +11.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Topline data from the trial is anticipated in the first half of 2027.”
matched to UPSTREAM MG · topline data
-
-
-
“Topline data from the trial is anticipated in the first half of 2027.”
matched to telitacicept · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (35)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseVor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1→ BD updateVor Bio acquired a next-generation long-acting BAFF/APRIL inhibitor (RC298) from RemeGen for ~$56M upfront, transforming the "single-asset bet" into a two-molecule franchise — but the market sold the news, and the dilution math deserves scrutiny before the 1H27 gMG binary.
- Nov 10, 2026ReleaseVor Bio To Participate in 2026 Jefferies Global Healthcare Conference
- Oct 30, 2026ReleaseVor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 10-QBD extracted 1 program update from this document → VOR pipeline
- Oct 30, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 10-Q
- Oct 30, 202610-QQuarterly report→ BD updateVor Bio's Q3 print confirms enrollment is locked, the 48-week Chinese gMG data adds an MSE durability layer (42.1%, ~83% of follow-up in remission), and management wasted no time refreshing the ATM with a new $150M facility — exactly the watch item flagged in the August update.
- Oct 22, 2026ReleaseTelitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy→ BD updateTELIGAN's two-year final analysis just delivered what the May NEJM interim promised: hard kidney-function preservation with an eGFR slope near zero (-0.6 vs -5.7 mL/min/1.73m²/year, p<0.001) and an 89% relative risk reduction in clinically meaningful eGFR decline — presented in the plenary session at ASN Kidney Week, while the stock sits 24.5% below the September enrollment-completion update.
- Sep 29, 2026ReleaseTelitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia GravisBD extracted 1 program update from this document → VOR pipeline
- Sep 8, 2026ReleaseVor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis→ BD updateUPSTREAM MG enrollment is complete — the operational execution risk is retired, the 1H27 readout clock is officially set, and Vor just announced a new oMG registrational program that widens the pipeline-in-a-product footprint before the binary lands.
- Sep 4, 2026S-3ASRAutomatic shelf registration
- Sep 1, 2026ReleaseVor Bio To Participate in Upcoming September Conferences
- Aug 11, 2026ReleaseVor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Aug 11, 202610-QQuarterly report
- Jul 21, 2026SCHEDULE 13D/A13D amendment
- Jul 7, 2026ReleaseVor Bio Appoints David Zaccardelli to Board of Directors
- Jul 7, 20268-KCurrent report: officer / director change
- Jun 12, 20268-KCurrent report: shareholder vote
- Jun 8, 2026ReleaseTelitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in ChinaBD extracted 1 program update from this document → VOR pipeline
- Jun 8, 2026ReleaseTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Jun 8, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- May 28, 2026ReleaseVor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
- May 14, 2026ReleaseVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
- May 13, 2026ReleaseVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
- May 13, 202610-QQuarterly report
- Apr 27, 2026S-3Shelf registration
- Apr 27, 2026DEFA14AProxy soliciting material
- Apr 27, 2026DEF 14AProxy statement
- Apr 21, 2026SCHEDULE 13D/A13D amendment
- Apr 15, 2026SCHEDULE 13D/A13D amendment
- Apr 10, 2026SCHEDULE 13D/A13D amendment
- Apr 8, 2026SCHEDULE 13D/A13D amendment
- Apr 1, 2026SCHEDULE 13D/A13D amendment
- Mar 30, 202610-KAnnual report
- Mar 27, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
- Mar 16, 2026SCHEDULE 13D/A13D amendment
19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13G/A13G amendment
- Aug 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 6, 2026SCHEDULE 13G/A13G amendment
- May 6, 2026SCHEDULE 13G/A13G amendment
- May 6, 2026EFFECTRegistration effective
- May 4, 2026CORRESPCORRESP
- May 1, 2026UPLOADUPLOAD
- Apr 27, 2026ARSAnnual report to shareholders
- Apr 1, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 30, 2026S-8Employee plan registration